Sign in
Not yet taking people in United StatesPhase 1

Safety and Tolerability of NTR-101 in Patients With Acute Alcohol-Associated Hepatitis

Key facts

Who runs it
Nterica Bio inc
Where
Coronado, United StatesSee the site
Trial code
Status
Not yet recruiting
Phase
Phase 1
People taking part
12 people, planned
Started
5 Nov 2025
Planned end
Jun 2026
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • bacteriophage preparation
Record updated
17 August 2025

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Diagnostic definition of acute alcohol-associated hepatitis based on well established standard disease markers
  • Able to provide written informed consent (either from patient or patient's legally authorized representative)
  • Male and female patients aged ≥18 years and ≤ 70 years of age
  • BMI ≥ 20 to ≤ 40 kg/m2
  • Enterococcus faecalis testing
  • Susceptibility to NTR-101
  • Women of child-bearing potential and male patients must agree to use a medically acceptable method of contraception/ birth control throughout the study duration

Who cannot take part

  • Participants taking systemic corticosteroids for a specified duration
  • Other or concomitant cause(s) of liver disease as a result of other conditions
  • Positive urine drug screen
  • Any significant systemic or major illness other than liver disease that, in the opinion of the investigator, would preclude the patient from participating in and completing the study or might complicated or exacerbated by the proposed treatments or might confound assessment of investigational product
  • Active bacterial or viral infections
  • Co-infection with HIV
  • Platelet count below specified ranges
  • INR and Serum creatinine levels above specified ranges
  • If female, known pregnancy, or has a positive serum pregnancy test, or lactating/ breastfeeding
  • Participants considered at high risk for alcohol withdrawal according to the clinical institute withdrawal assessment (CIWA-Ar) protocol

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in United States

  • Southern California Research Center, IncCoronado, United StatesContact: Kasey SeyerNot yet recruiting

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn about the safety and tolerability of NTR-101 in adult participants suffering from acute alcohol-associated hepatitis (AH).

Read full original descriptionShow less

The drug is intended for use in the treatment of AH where the presence of specific strains of E. faecalis play a contributing role.

The main questions it aims to answer are:

Are multiple doses of NTR-101 in participants with acute AH safe and well tolerated? What medical problems do participants have when taking NTR-101? Researchers will administer the drug and monitor participants in an inpatient center.

Participants will:

Be administered multiple ascending dose frequencies of NTR-101 every day for 7 days.

Stay in the clinic for 9 days (7 days of treatment) and present to clinic once every week for checkups and tests for 35 days.

Keep a diary of their symptoms until the checkups and tests are completed.

The 4 groups in the trial

  • Cohort 1Existing treatment, for comparison

    Dose 1

    Treatment: bacteriophage preparation

  • Cohort 2Existing treatment, for comparison

    Dose 2

    Treatment: Bacteriophage preparation

  • Cohort 3Existing treatment, for comparison

    Dose 3

    Treatment: bacteriophage preparation

  • Cohort 4Existing treatment, for comparison

    Dose 4

    Treatment: bacteriophage preparation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 1, Open Label Study to Evaluate Safety and Tolerability of NTR-101 in Patients With Acute Alcohol-Associated Hepatitis
Criteria questions
Built from NCT06750588, who can take part
Record updated
17 August 2025